PTH and secondary hyperparathyroidism: Indeed, vitamin D sterol therapy suppresses PTH while increasing circulating FGF23 levels dramatically in patients with end-stage kidney disease;[13] however, the effect of this form of therapy on skeletal expression of FGF23, sclerostin, and DMP1 in the context of advanced kidney disease and secondary hyperparathyroidism remains unknown.